Generate Biomedicines (NASDAQ:GENB) Stock Falls 6% - Here's Why

Key Points

• Generate Biomedicines shares fell 6% to about $13.01 in mid-day trading, with volume down 73% from the stock’s average daily level.
• The company’s latest quarterly results disappointed, reporting a loss of $0.52 per share versus the $0.48 loss analysts expected, on revenue of $6.31 million.
• Despite the decline, analyst sentiment remains broadly positive: six analysts rate GENB a Buy, supporting a “Moderate Buy” consensus and a $26.40 average price target.

Shares of Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) dropped 6% during mid-day trading on Tuesday. The company traded as low as $12.95 and last traded at $13.01. Approximately 225,037 shares traded hands during trading, a decline of 73% from the average daily volume of 843,769 shares. The stock had previously closed at $13.84.

Analyst Upgrades and Downgrades

GENB has been the subject of a number of research reports. Wall Street Zen raised shares of Generate Biomedicines from a "sell" rating to a "hold" rating in a research note on Saturday, September 26th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Generate Biomedicines in a report on Monday, October 5th. Finally, Weiss Ratings upgraded shares of Generate Biomedicines from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 25th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $26.40.

Generate Biomedicines Stock Performance

The firm's 50-day moving average price is $15.56 and its two-hundred day moving average price is $14.43. The firm has a market capitalization of $1.66 billion and a price-to-earnings ratio of -8.12.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million for the quarter. As a group, equities research analysts anticipate that Generate Biomedicines Inc will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Generate Biomedicines

Several hedge funds have recently added to or reduced their stakes in the stock. State Street Corp acquired a new stake in shares of Generate Biomedicines during the second quarter worth about $8,883,000. The Manufacturers Life Insurance Company bought a new stake in shares of Generate Biomedicines in the 2nd quarter valued at about $1,431,000. Squarepoint Ops LLC acquired a new stake in Generate Biomedicines in the 2nd quarter valued at about $530,000. AXQ Capital LP bought a new stake in Generate Biomedicines in the second quarter valued at approximately $218,000. Finally, Braidwell LP acquired a new position in shares of Generate Biomedicines in the second quarter valued at $55,398,000.

About Generate Biomedicines

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.